Filtered By:
Drug: Aspirin
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 3663 results found since Jan 2013.
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Young Patients Undergoing Carotid Endarterectomy Have Increased Rates of Recurrent Disease and Late Neurologic Events
CONCLUSIONS: Young patients undergoing CEA are more likely to be African American, female, and active smokers. They are more likely to present symptomatically and undergo non-elective CEA. Although perioperative outcomes are similar, younger patients are more likely to experience carotid occlusion or restenosis as well as subsequent neurological events, during relatively short follow-up. These data suggest that younger CEA patients may require more diligent follow-up, and a continued aggressive approach to medical management of atherosclerosis to prevent future events related to the operated artery, given the particularly ...
Source: Atherosclerosis - March 4, 2023 Category: Cardiology Authors: Molly Ratner Karan Garg Heepeel Chang William Johnson Mikel Sadek Thomas Maldonado Neal Cayne Jeffrey Siracuse Glenn Jacobowitz Caron Rockman Source Type: research
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
ConclusionsConsidering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2.5 mg twice daily should be considered the preferred regimen for S-ASCVD patients with low bleeding risk.
Source: American Journal of Cardiovascular Drugs - March 3, 2023 Category: Cardiology Source Type: research
Tirofiban Superior to Aspirin in Stroke Without Large Occlusion Tirofiban Superior to Aspirin in Stroke Without Large Occlusion
Among patients with disabling strokes without medium or large occlusions, more of those taking tirofiban had good function at 90 days than those on aspirin, results of the RESCUE BT2 trial show.Medscape Medical News
Source: Medscape Cardiology Headlines - March 2, 2023 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Efficacy and safety of low dose aspirin plus clopidogrel in the treatment of elderly patients with symptomatic intracranial artery stenosis
ConclusionIn this study, the safety of low dose aspirin combined with clopidogrel proved to be equally efficient and significantly safer than those of conventional dose within 24 months in elderly patients with sICAS. However, the small size of this study limits the validity of the results. Further larger longitudinal and randomized controlled trials are necessary to evaluate the role of low dose DAPT in the patients with sICAS.
Source: Frontiers in Neurology - March 2, 2023 Category: Neurology Source Type: research
Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research
Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population
CONCLUSION: Until proven otherwise, aspirin has only a limited place in individuals between 35 and 65 years without a cardiovascular history. We showed how simulating therapeutic strategies on a realistic virtual population could be used for best applying available evidence.PMID:36841655 | DOI:10.1016/j.therap.2023.01.011
Source: Therapie - February 25, 2023 Category: Psychiatry & Psychology Authors: Mor Fall Guillaume Grenet Hai-Ha Le Behrouz Kassa ï Jean-Christophe Lega R émy Boussageon Sabine Mainbourg Ivanny Marchant Johanne Gafsi Amadou Moctar Dieye Fran çois Gueyffier Source Type: research
Neuroprotective Effects of Geopung-Chunghyuldan Based on Its Salvianolic Acid B Content Using an In Vivo Stroke Model
CONCLUSIONS: The salvianolic acid B content of Salviae miltiorrhizae Radix affects the neuroprotection effect of GCD. Stable, raw Salviae miltiorrhizae Radix is essential for GCD homogenization.PMID:36826049 | PMC:PMC9955915 | DOI:10.3390/cimb45020104
Source: Current Issues in Molecular Biology - February 24, 2023 Category: Molecular Biology Authors: Han-Gyul Lee Seungwon Kwon Sang-Kwan Moon Seung-Yeon Cho Seong-Uk Park Woo-Sang Jung Jung-Mi Park Chang-Nam Ko Ki-Ho Cho Source Type: research
Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease
Eur J Med Res. 2023 Feb 23;28(1):93. doi: 10.1186/s40001-023-01050-5.ABSTRACTIschemic cerebrovascular disease (ICVD) is a major cause of mortality and disability worldwide and is often caused by atherosclerosis. As a systemic disease, atherosclerosis usually affects multiple vascular beds, mainly including cerebral, coronary, and peripheral arteries. Therefore, ICVD is easily complicated by lower-extremity peripheral arterial disease (PAD). ICVD patients with PAD have more serious symptoms and a worse prognosis, however, neurologists might neglect the evaluation and management of the coexistent PAD, and there is still a la...
Source: Atherosclerosis - February 24, 2023 Category: Cardiology Authors: Lu-Guang Li Xin Ma Source Type: research
Neuroprotective Effects of Geopung-Chunghyuldan Based on Its Salvianolic Acid B Content Using an In Vivo Stroke Model
CONCLUSIONS: The salvianolic acid B content of Salviae miltiorrhizae Radix affects the neuroprotection effect of GCD. Stable, raw Salviae miltiorrhizae Radix is essential for GCD homogenization.PMID:36826049 | PMC:PMC9955915 | DOI:10.3390/cimb45020104
Source: Current Issues in Molecular Biology - February 24, 2023 Category: Molecular Biology Authors: Han-Gyul Lee Seungwon Kwon Sang-Kwan Moon Seung-Yeon Cho Seong-Uk Park Woo-Sang Jung Jung-Mi Park Chang-Nam Ko Ki-Ho Cho Source Type: research
